Citations

Clear

16281 citation(s) found for "Yu, David".

Chromosomal microarray impacts clinical management
Riggs, Erin Rooney , Wain, Karen E. , Riethmaier, Darlene, Smith‐Packard, Bethanny, Faucett, W. Andrew , Hoppman, Nicole L., Thorland, Erik C., Miller, David T. , Patel, Viren

Mayo Clinic

Clinical Genetics | January 25, 2013 | Volume: 85 | Issue: 2 | Pages: 147-153

10.1111/cge.12107 | PMID 23347240 Get It

Chromosomal microarray analysis (CMA) is standard of care, first‐tier clinical testing for detection of genomic copy number variation among patients with developmental disabilities. Although diagnostic yield is higher than traditional cytogenetic testing, management impact has not been well studied. We surveyed genetic services providers regarding CMA ordering practices and perceptions about reimbursement. Lack of insurance coverage because of perceived lack of clinical utility was cited among the most frequent reasons why CMA was not ordered when warranted. We compiled a list of genomic regions where haploinsufficiency or triplosensitivity cause genetic conditions with documented management recommendations, estimating that at least 146 conditions potentially diagnosable by CMA testing have published literature supporting specific clinical management implications. Comparison with an existing clinical CMA database to determine the proportion of cases involving these regions showed that CMA diagnoses associated with such recommendations are found in approximately 7% of all cases (n = 28,526). We conclude that CMA impacts clinical management at a rate similar to other genetic tests for which insurance coverage is more readily approved. The information presented here can be used to address barriers that continue to contribute to inequities in patient access and care in regard to CMA testing.
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease
Yab, Tracy C. , Hussain, Fareeda Taher Nazer, Garrity-Park, Megan, Sandborn, William J. , Loftus, Edward V. , Wolff, B. G., Smyrk, Thomas C. , Zou, Hongzhi , Ahlquist, David A. , Kisiel, John B. , Taylor, William R. , Itzkowitz, Steven H. , Rubin, David T. , Mahoney, Douglas W. , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 24, 2013 | Volume: 37 | Issue: 5 | Pages: 546-554

10.1111/apt.12218 | PMID 23347191 Get It

SummaryBackgroundCurrent approaches to the detection of colorectal neoplasia associated with inflammatory bowel disease (IBD‐CRN) are suboptimal.AimTo test the feasibility of using stool assay of exfoliated DNA markers to detect IBD‐CRN.MethodsThis investigation comprised tissue and stool studies. In the tissue study, gene sequencing and methylation assays were performed on candidate genes using tissue DNA from 25 IBD‐CRNs and from 25 IBD mucosae without CRN. Mutations on p53, APC, KRAS, BRAF or PIK3CA genes were insufficiently informative, but several aberrantly methylated genes were highly discriminant. In the stool study, we evaluated candidate methylated genes (vimentin, EYA4, BMP3, NDRG4) in a prospective blinded study on buffered stools from 19 cases with known IBD‐CRN and 35 age‐ and sex‐matched IBD controls without CRN. From stool‐extracted DNA, target genes were assayed using quantitative allele‐specific real‐time target and signal amplification method.ResultsIBD‐CRN cases included 17 with ulcerative colitis (UC) and two with Crohn's disease (CD); nine had cancer and 10 had dysplasia. Controls included 25 with UC and 10 with CD. Individually, BMP3, vimentin, EYA4 and NDRG4 markers showed high discrimination in stools with respective areas under the ROC curve of 0.91, 0.91, 0.85 and 0.84 for total IBD‐CRN and of 0.97, 0.97, 0.95 and 0.85 for cancer. At 89% specificity, the combination of BMP3 and mNDRG4 detected 9/9 (100%) of CRC and 80% of dysplasia, 4/4 (100%) of high grade and 4/6 (67%) of low grade.ConclusionThese findings demonstrate the feasibility of stool DNA testing for non‐invasive detection of colorectal neoplasia associated with inflammatory bowel disease.
Percutaneous sacroplasty using CT guidance for pain palliation in sacral insufficiency fractures
Dougherty, Ryne W., McDonald, Jennifer S, Cho, Yong Woon, Wald, John T. , Thielen, Kent R. , Kallmes, David F. , McDonald, Jennifer S

Mayo Clinic

Journal of NeuroInterventional Surgery | January 24, 2013 | Volume: 6 | Issue: 1 | Pages: 57-60

10.1136/neurintsurg-2012-010599 | PMID 23345629 Get It

Background and objective Sacroplasty has emerged as a treatment option for patients with painful osteoporotic sacral insufficiency fractures. We report short-term outcomes in a consecutive cohort of patients treated with sacroplasty. Methods We retrospectively reviewed 57 patients treated with sacroplasty for painful osteoporotic sacral fractures at our institution between 2004 and 2011. An 11-point numerical rating scale pain score was recorded at rest and at activity pre- and post-procedure. Opioids prescribed to the patient both pre- and post-procedure were recorded. Results Mean duration of pain prior to sacroplasty was 3 weeks (IQR 2–5). Procedural complications were minimal. Median post-procedure follow-up time was 2.5 weeks (IQR 1–5) among 45 patients with available data. Thirty-seven (82%) of the 45 patients experienced a numerical or descriptive decrease from initial pain at follow-up. Median activity pain scores collected from 13 patients decreased from 10 (IQR 8.5–10) pre-procedure to 6 (IQR 4–6.8) post-procedure (p<0.0001), and median rest pain scores collected from 29 patients decreased from 7 (IQR 4–8.5) to 2 (IQR 1–3.5)(p<0.0001). Twenty-two (76%) of 29 patients had at least a 30% decrease in rest pain scores. The median number of opioids prescribed per patient decreased from 1 (IQR 1–2) pre-procedure to 0 (IQR 0–1) post-procedure (p<0.0001). Thirty-four of 57 patients (60%) had decreased opioid usage, 15 (26%) patients had unchanged usage and 8 (14%) had increased usage. Conclusions Our series demonstrates that sacroplasty is a safe and effective treatment in patients with painful osteoporotic insufficiency fractures.
Percutaneous Ablation of Renal Masses Measuring 3.0 cm and Smaller: Comparative Local Control and Complications After Radiofrequency Ablation and Cryoablation
Atwell, Thomas D. , Schmit, Grant D. , Boorjian, Stephen A. , Mandrekar, Jay , Weisbrod, Adam J. , Chow, George K. , Leibovich, Bradley C. , Callstrom, Matthew R. , Patterson, David E., Lohse, Christine M. , Thompson, R. Houston, Kurup, A. Nicholas

Mayo Clinic

American Journal of Roentgenology | January 23, 2013 | Volume: 200 | Issue: 2 | Pages: 461-466

10.2214/ajr.12.8618 | PMID 23345372 Get It

Faculty Opinions recommendation of Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962062.793468755 Get It

Faculty Opinions recommendation of Interventions for dysphagia and nutritional support in acute and subacute stroke.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962277.793468753 Get It

Faculty Opinions recommendation of Interventions for oropharyngeal dysphagia in children with neurological impairment.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962207.793468752 Get It

Faculty Opinions recommendation of Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962508.793468756 Get It

Faculty Opinions recommendation of Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717961959.793468648 Get It

Deletions in 16q24.2 are associated with autism spectrum disorder, intellectual disability and congenital renal malformation
Handrigan, Gregory R., Lionel, Anath C. , Pinsk, Maury , Vaags, Andrea K., Marshall, Christian R. , Dyack, Sarah , Fernandez, Bridget A. , Stegman, Joseph C., Shaffer, Lisa G. , Goodenberger, McKinsey L. , Hodge, Jennelle C. , Cain, Jason E. , Babul‐Hirji, Riyana, Stavropoulos, Dimitri J. , Yiu, Verna, Scherer, Stephen W. , Rosenblum, Norman D. , Chitayat, David A. , Escobar, Luis Fernando , Rosenfeld, Jill A. , Scherer, Stephen W , Goodenberger, McKinsey , Marshall, Christian R.

Mayo Clinic

Journal of Medical Genetics | January 18, 2013 | Volume: 50 | Issue: 3 | Pages: 163-173

10.1136/jmedgenet-2012-101288 | PMID 23335808 Get It

Background The contribution of copy-number variation (CNV) to disease has been highlighted with the widespread adoption of array-based comparative genomic hybridisation (aCGH) and microarray technology. Contiguous gene deletions involving ANKRD11 in 16q24.3 are associated with autism spectrum disorder (ASD) and intellectual disability (ID), while 16q24.1 deletions affecting FOXF1 are associated with congenital renal malformations, alveolar capillary dysplasia, and various other abnormalities. The disease associations of deletions in the intervening region, 16q24.2, have only been defined to a limited extent. Aim To determine whether deletions affecting 16q24.2 are correlated with congenital anomalies. Methods 35 individuals, each having a deletion in 16q24.2, were characterised clinically and by aCGH and/or SNP-genotyping microarray. Results Several of the 35 16q24.2 deletions identified here closely abut or overlap the coding regions of FOXF1 and ANKRD11, two genes that have been previously associated with the disease. 25 patients were reported to have ASD/ID, and three were found to have bilateral hydronephrosis. 14 of the deletions associated with ASD/ID overlap the coding regions of FBXO31 and MAP1LC3B. These same genes and two others, C16orf95 and ZCCHC14, are also included in the area of minimal overlap of the three deletions associated with hydronephrosis. Conclusions Our data highlight 16q24.2 as a region of interest for ASD, ID and congenital renal malformations. These conditions are associated, albeit without complete penetrance, with deletions affecting C16orf95, ZCCHC14, MAP1LC3B and FBXO31. The function of each gene in development and disease warrants further investigation.